Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 19,078 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus

NCT01270282
View directory record Official record
Conditions
Tinnitus
Interventions
AM-101 0.81 mg/mL, Placebo
Drug
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Gainsville, Florida • Kansas City, Kansas • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

NCT01489059
View directory record Official record
Conditions
Melanoma
Interventions
BMS-982470 (recombinant interleukin-21), Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

NCT01603459
View directory record Official record
Conditions
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

NCT01649180
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Phase 3 Interventional Results available

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

NCT01770379
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 17, 2026, 11:09 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

NCT04838678
View directory record Official record
Conditions
Hypertension, Obesity
Interventions
Neuropeptide Y
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 11:09 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

NCT02563678
View directory record Official record
Conditions
Infection
Interventions
Hyperbaric Oxygen, Hyperbaric Air/Oxygen, Normobaric oxygen
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

Biochemotherapy With Temozolomide for Metastatic Melanoma

NCT00505635
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide, Velban, Cisplatin, Interleukin-2, Intron-A, Thalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

NCT01291017
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PD0332991
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 17, 2026, 11:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Early Phase 1 Interventional

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

NCT03812562
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Yttrium Y 90 Glass Microspheres
Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808

NCT01723488
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[F18] T808
Radiation
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated Phase 1 Interventional

Vascular Sealant Study

NCT00618358
View directory record Official record
Conditions
Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions
Vascular Sealant System, Gelfoam/Thrombin
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843
View directory record Official record
Conditions
HIV Infections, Streptococcus Pneumoniae
Interventions
pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 17, 2026, 11:09 PM EDT
Terminated No phase listed Observational

Genetic Mechanisms in Human Hypertension

NCT01456208
View directory record Official record
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

NCT03459040
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991
View directory record Official record
Conditions
Skin Aging
Interventions
Placebo, Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 17, 2026, 11:09 PM EDT
Recruiting Early Phase 1 Interventional

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions
Encorafenib Pill, Binimetinib Pill, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

NCT01932060
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Oxytocin Infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 17, 2026, 11:09 PM EDT